CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
intranasal oxytocin spray +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02275611
NCT02275611Phase 2Completed
CompareCT.gov

Oxytocin Treatment of Alcohol Dependence: A Randomized, Placebo-Controlled Trial

University of North Carolina, Chapel Hill·interventional·Posted Oct 27, 2014·Updated Apr 4, 2017

In Brief

A Phase 2 clinical trial evaluating intranasal oxytocin spray and Intranasal Placebo Spray for Alcohol Withdrawal and Alcohol Dependence. Completed, enrolled 13 participants.

Detailed Summary

This study will test in individuals who have alcohol dependence (alcohol addiction) the hypotheses 1) that intranasal oxytocin treatment will decrease withdrawal symptoms during medical detoxification and 2) that intranasal oxytocin treatment for 12 weeks in the outpatient setting will decrease drinking.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Withdrawal, Alcohol Dependence
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 27, 2014
Enrollment StartJan 1, 2013
Primary CompletionDec 1, 2013
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11.7 years ago

Interventions

intranasal oxytocin spraydrug

Administration of oxytocin in a nasal spray

Intranasal Placebo Spraydrug

Intranasal Placebo Spray